Bills · H.R. 586 · Armed Forces and National Security
Vietnam Veterans Liver Fluke Cancer Study Act
H.R. 586, introduced January 21, 2025 by Nick LaLota (R-NY) with 8 cosponsors. Received in the Senate and Read twice and referred to the Committee on Veterans' Affairs. 1 organization reported lobbying on it from January 2025 through September 2026.
Passage votes
1Near-unanimous
Organizations lobbying on it
1
Said where they stood
0of 1, in their reports
Cosponsors
8
What the bill does
The Congressional Research Service's summary of the bill as introduced in the House, January 21, 2025. The version Congress voted on may differ.
This bill requires the Department of Veterans Affairs (VA) to conduct an epidemiological study and report on the prevalence of cholangiocarcinoma (bile duct cancer) in veterans who served in the Vietnam theater of operations during the Vietnam era. The study must identify the rate of incidence of cholangiocarcinoma in such veterans and in U.S. residents.
The bill also requires the VA to track and report on the prevalence of cholangiocarcinoma using the Veterans Affairs Central Cancer Registry. Additionally, the VA must periodically submit follow-up reports to Congress regarding the epidemiological study and information collected from the cancer registry regarding the prevalence of bile duct cancer.
Each recorded vote on passing the bill, by party. Procedural votes (rules, motions to recommit, cloture) and amendments aren't shown: they mostly follow party lines whatever the bill says.
House, April 7, 2025 · Passage (two-thirds needed)
Organizations whose quarterly lobbying reports name H.R. 586, January 2025 through September 2026. Reports list what was lobbied on, not the position taken: an organization here may have backed the bill, opposed it, or wanted one part of it changed. None of 1 said which in the report. Reports don't break spending down by bill, so there's no dollar figure for this one.
Organizations whose lobbying reports name H.R. 586